BeOne Medicines Ltd.

ONC

BeOne Medicines Ltd.

ONC

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-23Shares Purchased (TTM):0Shares Sold (TTM):135,725

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:34,066,399Shares Outstanding:110,957,836Institutional Ownership Pct.:30.70%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	5,098	4,792	4,548	4,037	2,756	2,516	2,627	2,702	2,593	2,793	3,172	3,067
Debt Securities Available For Sale Excluding Accru…	-	-	-	-	-	-	-	-	-	0	3	107
Accounts Receivable Net Current	1,056	938	865	863	771	717	676	569	529	435	358	309
Restricted Cash And Cash Equivalents At Carrying V…	-	-	-	-	-	-	-	-	-	-	11	12
Inventory Net	733	682	608	532	503	495	495	432	443	447	416	317
Prepaid Expense And Other Assets Current	329	190	213	233	281	168	193	209	274	232	257	242
Assets Current	7,216	6,601	6,234	5,664	4,310	3,896	3,992	3,912	3,839	3,908	4,203	4,054
Property Plant And Equipment Net	1,643	1,641	1,642	1,628	1,616	1,599	1,578	1,563	1,516	1,418	1,324	1,178
Operating Lease Right Of Use Asset	146	145	148	140	146	146	139	101	104	88	95	99
Finite Lived Intangible Assets Net	61	62	63	64	65	50	51	54	54	55	57	54
Other Assets Noncurrent	110	104	102	136	162	150	160	201	199	199	125	141
Assets Noncurrent	1,960	1,952	1,955	1,968	1,988	1,945	1,929	1,919	1,873	1,760	1,602	1,471
Assets	9,176	8,554	8,189	7,633	6,298	5,842	5,921	5,831	5,712	5,668	5,805	5,525
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	470	424	479	384	361	364	405	308	333	357	315	342
Accrued Liabilities Current	1,264	1,079	1,109	1,002	909	692	804	717	647	569	694	506
Taxes Payable Current	76	64	42	11	6	34	26	15	5	27	23	20
Operating Lease Liability Current	22	21	21	16	17	18	18	18	18	19	22	23
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Other Long Term Debt Current	-	-	-	52	-	-	-	-	-	-	-	-
Short Term Borrowings	-	9	-	813	-	-	-	-	-	-	-	-
Long Term Debt Current	191	116	57	-	808	763	852	864	852	827	688	329
Liabilities Current	2,119	1,812	1,829	2,368	2,210	1,984	2,215	2,025	1,939	1,882	1,810	1,283
Liabilities Noncurrent
Loans Payable	-	-	-	140	-	-	-	-	-	-	-	-
Other Long Term Debt Noncurrent	-	-	-	833	-	-	-	-	-	-	-	-
Long Term Debt Noncurrent	882	963	962	-	146	160	166	188	185	199	198	202
Operating Lease Liability Noncurrent	48	50	53	51	54	55	44	32	35	18	22	25
Deferred Income Tax Liabilities Net	57	56	53	47	44	43	42	16	16	16	16	16
Other Liabilities Noncurrent	78	82	80	64	63	66	67	51	52	49	51	42
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Noncurrent	1,882	1,982	1,999	1,135	318	358	374	369	407	426	458	478
Liabilities	4,002	3,793	3,827	3,503	2,528	2,342	2,589	2,395	2,346	2,307	2,268	1,762
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	13,055	12,906	12,759	12,617	12,395	12,247	12,088	11,974	11,840	11,705	11,599	11,503
Accumulated Other Comprehensive Income Loss Net Of…	-25	-53	-78	-101	-114	-142	-149	-84	-140	-132	-99	-145
Retained Earnings Accumulated Deficit	-7,856	-8,093	-8,320	-8,386	-8,511	-8,606	-8,607	-8,455	-8,334	-8,213	-7,962	-7,594
Stockholders Equity	5,174	4,760	4,361	4,129	3,770	3,500	3,332	3,436	3,366	3,360	3,537	3,763
Liabilities And Stockholders Equity	9,176	8,554	8,189	7,633	6,298	5,842	5,921	5,831	5,712	5,668	5,805	5,525
Common Stock Number Of Sh…
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	-	-	-	-	-	731	731	731	731	731	731	731
Common Stock Shares Issued	119	119	119	119	119	108	107	107	106	105	105	104
Shares Outstanding	113	111	111	111	110	108	107	107	106	105	105	104

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-8.11%	-10.67%	4.02%	-	-	-	-	-	-	-	-	-
2025	5.74%	3.85%	25.50%	2.52%	9.23%	4.12%	2.48%	-6.01%	2.09%	-14.61%	0.47%	-9.03%
2024	-9.48%	-13.24%	-1.16%	8.52%	23.59%	20.42%	6.19%	-6.62%	16.19%	-9.48%	-17.03%	-17.96%
2023	-	-	-	-	-	-	-1.09%	-4.85%	-14.59%	-5.14%	-19.18%	7.86%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.40	3.64	3.41	2.39	1.95	1.96	1.80	1.93	1.98	2.08	2.32	3.16
Quick Ratio	2.90	3.16	2.96	2.07	1.60	1.63	1.49	1.62	1.61	1.72	1.95	2.72
Working Capital	5.10B	4.79B	4.40B	3.30B	2.10B	1.91B	1.78B	1.89B	1.90B	2.03B	2.39B	2.77B
Leverage & Debt
Debt to Equity	0.77	0.80	0.88	0.85	0.67	0.67	0.78	0.70	0.70	0.69	0.64	0.47
Interest Coverage TTM	12.20	15.62	24.81	7.07	-3.01	-7.65	-11.88	-3.39	-2.99	-4.95	-6.01	-17.02
Debt Ratio	0.44	0.44	0.47	0.46	0.40	0.40	0.44	0.41	0.41	0.41	0.39	0.32
Efficiency & Turnover
Asset Turnover TTM	0.79	0.80	0.76	0.74	0.76	0.73	0.65	0.58	0.54	0.48	0.40	0.36
Days Sales Outstanding TTM	54.40	52.64	52.65	52.57	52.01	50.37	49.54	48.32	48.84	49.21	39.43	41.25
Receivables Turnover TTM	6.71	6.93	6.93	6.94	7.02	7.25	7.37	7.55	7.47	7.42	9.26	8.85
Per Share Metrics
Diluted EPS TTM	5.66	4.43	2.53	0.60	-1.58	-3.53	-6.12	-8.12	-5.00	-7.52	-8.45	-8.97
Free Cash Flow Per Share TTM	11.92	10.05	8.63	4.94	2.26	-1.69	-6.01	-9.50	-12.38	-15.65	-17.78	-18.21
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	88.89%	88.31%	87.49%	86.19%	85.52%	84.81%	84.41%	83.74%	84.98%	84.69%	84.55%	84.23%
Operating Profit Margin TTM	15.06%	11.95%	8.37%	3.67%	-2.21%	-7.08%	-14.91%	-8.92%	-10.00%	-18.87%	-25.67%	-58.63%
Net Profit Margin TTM	10.70%	8.94%	5.37%	1.38%	-3.89%	-9.40%	-16.92%	-25.94%	-16.91%	-28.39%	-35.86%	-43.52%
Growth Metrics
Net Revenue Growth (1Y)	34.35%	37.44%	40.23%	49.92%	47.33%	51.16%	54.96%	50.46%	71.01%	77.42%	73.65%	76.38%
Net Income Growth (1Y)	-469.12%	-230.75%	-144.50%	-107.97%	-66.08%	-49.98%	-26.87%	-10.32%	-69.77%	-59.20%	-56.12%	-55.79%
EPS Growth (1Y)	-458.35%	-226.00%	-142.96%	-107.66%	-67.21%	-51.22%	-27.50%	-11.37%	-69.79%	-59.24%	-56.65%	-56.29%
Valuation Metrics
P/E TTM	48.49	64.23	115.48	547.78	-147.61	-74.17	-30.16	-27.63	-28.52	-20.79	-21.35	-19.62
P/B TTM	6.15	6.92	7.60	9.09	6.95	8.32	5.84	6.92	4.44	4.85	5.32	5.00
P/S TTM	5.19	5.74	6.20	7.55	5.75	6.97	5.10	7.17	4.82	5.90	7.66	8.54
Market Cap	31.80B	32.95B	33.13B	37.55B	26.22B	29.10B	19.45B	23.78B	14.94B	16.31B	18.83B	18.83B
Enterprise Value	27.59B	29.19B	29.61B	34.25B	24.42B	27.50B	17.83B	22.11B	13.36B	14.53B	16.53B	16.28B
Calculated Values
Free Cash Flow TTM	1.33B	1.11B	941.74M	544.60M	244.84M	-180.47M	-633.29M	-1.01B	-1.30B	-1.63B	-1.86B	-1.91B
Net Debt	-4.21B	-3.77B	-3.53B	-3.30B	-1.80B	-1.61B	-1.62B	-1.66B	-1.58B	-1.78B	-2.30B	-2.55B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Oyler, John

Title: Chief Executive Officer

Shares: 3,410

Price/Share: $274.17

Value: $934,919.70

Shares Owned: -

Relationship: Director,Officer

Ownership: Direct

2026-06-23Sale

Owner: Wu, Xiaobin

Title: President and COO

Shares: 1,292

Price/Share: $276.26

Value: $356,927.92

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Wang, Lai

Title: President, Global Head of R&D

Shares: 1,068

Price/Share: $276.74

Value: $295,558.32

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-16Sale

Owner: Oyler, John

Title: Chief Executive Officer

Shares: 3,693

Price/Share: $265.85

Value: $981,784.05

Shares Owned: -

Relationship: Director,Officer

Ownership: Direct

2026-06-16Sale

Owner: Wu, Xiaobin

Title: President and COO

Shares: 1,357

Price/Share: $266.76

Value: $361,993.32

Shares Owned: -

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	3,410	274.17	$934,919.70	0	4
2026-06-23	Wu, Xiaobin	Officer	President and COO	Direct	Sale	1,292	276.26	$356,927.92	0	4
2026-06-23	Wang, Lai	Officer	President, Global Head of R&D	Direct	Sale	1,068	276.74	$295,558.32	0	4
2026-06-16	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	3,693	265.85	$981,784.05	0	4
2026-06-16	Wu, Xiaobin	Officer	President and COO	Direct	Sale	1,357	266.76	$361,993.32	0	4
2026-06-16	Wang, Lai	Officer	President, Global Head of R&D	Direct	Sale	1,169	265.39	$310,240.91	0	4
2026-06-16	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	590	265.98	$156,928.20	0	4
2026-06-11	Wang, Lai	Officer	President, Global Head of R&D	Direct	Sale	756	261.00	$197,316.00	0	4
2026-06-11	Ball, Titus B.	Officer	Principal Accounting Officer	Direct	Sale	169	256.96	$43,426.24	0	4
2026-06-11	Rosenberg, Aaron	Officer	Chief Financial Officer	Direct	Sale	631	257.74	$162,633.94	0	4
2026-06-11	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	428	257.64	$110,269.92	0	4
2026-06-11	Wu, Xiaobin	Officer	President and COO	Direct	Sale	626	261.20	$163,511.20	0	4
2026-06-11	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	1,949	257.73	$502,315.77	0	4
2026-06-08	Wang, Lai	Officer	President, Global Head of R&D	Direct	Sale	1,367	270.03	$369,131.01	0	4
2026-06-08	Wu, Xiaobin	Officer	President and COO	Direct	Sale	1,484	269.94	$400,590.96	0	4
2026-06-08	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	4,940	270.76	$1,337,554.40	0	4
2026-06-08	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	871	270.75	$235,823.25	0	4
2026-06-08	Ball, Titus B.	Officer	Principal Accounting Officer	Direct	Sale	136	271.57	$36,933.52	0	4
2026-06-01	Yi, Qingqing	Director	-	Direct	Sale	235	279.13	$65,595.55	0	4
2026-05-22	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	212	309.59	$65,633.08	0	4
2026-05-22	Riva, Alessandro	Director	-	Direct	Sale	212	309.51	$65,616.12	0	4
2026-05-22	Dugan, Margaret	Director	-	Direct	Sale	212	309.60	$65,635.20	0	4
2026-05-22	Baker, Bros. Advisors Lp,…	Director	-	Indirect	Sale	10,998	23.82	$261,972.36	142,566	4
2026-05-13	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	332	310.72	$103,159.04	0	4
2026-04-08	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	332	311.59	$103,447.88	0	4
2026-03-11	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	341	300.00	$102,300.00	0	4
2026-02-04	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	1,660	349.40	$580,004.00	0	4
2026-01-07	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	664	331.76	$220,288.64	0	4
2025-12-16	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	24,369	302.92	$7,381,857.48	0	4
2025-12-11	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	332	325.00	$107,900.00	0	4
2025-11-26	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	2,627	341.34	$896,700.18	0	4
2025-11-17	Wu, Xiaobin	Officer	President and COO	Direct	Sale	3,991	381.25	$1,521,568.75	0	4
2025-11-13	Wu, Xiaobin	Officer	President and COO	Direct	Sale	6,009	380.69	$2,287,566.21	0	4
2025-11-12	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	996	349.38	$347,982.48	0	4
2025-10-08	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	10,671	349.79	$3,732,609.09	0	4
2025-09-16	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	27,803	326.00	$9,063,778.00	0	4
2025-09-10	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	10,006	326.13	$3,263,256.78	0	4
2025-09-09	Wang, Lai	Officer	Global Head of R&D	Indirect	Sale	5,000	350.06	$1,750,300.00	0	4
2025-09-05	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	2,665	337.00	$898,105.00	0	4
2025-09-02	Ball, Titus B.	Officer	Principal Accounting Officer	Direct	Sale	122	326.76	$39,864.72	0	4
2025-08-14	Wu, Xiaobin	Officer	President and COO	Direct	Sale	39,936	304.70	$12,168,499.20	0	4
2025-08-13	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	11,013	300.40	$3,308,305.20	0	4
2025-08-01	Rosenberg, Aaron	Officer	Chief Financial Officer	Direct	Sale	1,190	290.47	$345,659.30	0	4
2025-07-30	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	920	304.60	$280,232.00	0	4
2025-07-30	Wang, Lai	Officer	Global Head of R&D	Indirect	Sale	259	305.00	$78,995.00	0	4
2025-07-18	Wang, Lai	Officer	Global Head of R&D	Indirect	Sale	700	300.00	$210,000.00	0	4
2025-07-09	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	27,802	253.58	$7,050,031.16	0	4
2025-06-24	Wang, Xiaodong	Director,Other	-	Direct	Sale	2,007	265.81	$533,480.67	0	4
2025-06-23	Wu, Xiaobin	Officer	President and COO	Direct	Sale	1,363	260.00	$354,380.00	0	4
2025-06-23	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	3,174	262.24	$832,349.76	0	4
2025-06-23	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	1,028	260.00	$267,280.00	0	4
2025-06-17	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	470	251.37	$118,143.90	0	4
2025-06-17	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	1,460	256.49	$374,475.40	0	4
2025-06-17	Wu, Xiaobin	Officer	President and COO	Direct	Sale	630	250.87	$158,048.10	0	4
2025-06-16	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	422	266.50	$112,463.00	0	4
2025-06-11	Ball, Titus B.	Officer	Principal Accounting Officer	Direct	Sale	134	258.36	$34,620.24	0	4
2025-06-10	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	263.10	$10,987,056.00	0	4
2025-06-06	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	1,402	252.77	$354,383.54	0	4
2025-06-06	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	700	256.29	$179,403.00	0	4
2025-06-06	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	5,127	253.38	$1,299,079.26	0	4
2025-06-06	Wu, Xiaobin	Officer	President and COO	Direct	Sale	1,934	253.43	$490,133.62	0	4
2025-05-13	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	224.06	$9,356,745.60	0	4
2025-04-14	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	243.52	$10,169,395.20	0	4
2025-04-01	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	51,921	282.13	$14,648,471.73	0	4
2025-03-18	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	261.12	$10,904,371.20	0	4
2025-03-14	Wu, Xiaobin	Officer	President, COO & GM China	Indirect	Sale	0	0.00	$0.00	0	4
2025-03-10	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	41,210	242.91	$10,010,321.10	0	4
2025-03-07	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	58,590	250.34	$14,667,420.60	0	4
2025-03-06	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	40,109	260.48	$10,447,592.32	0	4
2025-03-05	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	51,921	261.88	$13,597,071.48	0	4
2025-03-04	Wang, Xiaodong	Director,Other	-	Indirect	Sale	8,146	254.67	$2,074,541.82	0	4
2025-03-03	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	101,000	244.98	$24,742,980.00	0	4
2025-02-28	Wu, Xiaobin	Officer	President, COO & GM China	Indirect	Sale	0	0.00	$0.00	0	4
2025-02-28	Baker, Bros. Advisors (Gp…	Director	-	Indirect	Sale	732,827	260.00	$190,535,020.00	730,642	4
2025-02-27	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	1,205	275.00	$331,375.00	0	4
2025-02-21	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	1,202	258.58	$310,813.16	0	4
2025-02-21	Wang, Lai	Officer	Global Head of R&D	Indirect	Sale	5,000	257.41	$1,287,050.00	0	4
2025-02-20	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	21,267	240.07	$5,105,568.69	0	4
2025-02-04	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	225.64	$9,422,726.40	0	4
2025-01-07	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	177.42	$7,409,059.20	0	4
2024-12-10	Wang, Xiaodong	Director,Other	-	Direct	Sale	41,760	189.29	$7,904,750.40	0	4
2024-12-09	Baker, Brothers Life Scie…	Director	-	Indirect	Sale	1,037,017	197.26	$204,561,973.42	791,493	4
2024-12-06	Wu, Xiaobin	Officer	President, COO & GM China	Indirect	Sale	0	0.00	$0.00	0	4
2024-12-02	Hillhouse, Investment Man…	TenPercentOwner	-	Indirect	Sale	17,842,500	200.00	$3,568,500,000.00	125,045,741	4
2024-11-26	Wang, Xiaodong	Director,Other	-	Direct	Sale	40,468	189.69	$7,676,374.92	0	4
2024-10-08	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	6,175	232.77	$1,437,354.75	0	4
2024-09-30	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	1,202	237.10	$284,994.20	0	4
2024-09-27	Wang, Lai	Officer	Global Head of R&D	Indirect	Sale	5,000	220.35	$1,101,750.00	0	4
2024-09-19	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	4,500	200.14	$900,630.00	0	4
2024-09-03	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	5,556	190.13	$1,056,362.28	0	4
2024-09-03	Ball, Titus B.	Officer	Principal Accounting Officer	Direct	Sale	137	189.94	$26,021.78	0	4
2024-07-30	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	834	160.57	$133,915.38	0	4
2024-07-01	Wang, Julia Aijun	Officer	Chief Financial Officer	Direct	Sale	472	143.90	$67,920.80	0	4
2024-06-24	Wang, Julia Aijun	Officer	Chief Financial Officer	Direct	Sale	899	155.66	$139,938.34	0	4
2024-06-24	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	1,064	160.45	$170,718.80	0	4
2024-06-24	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	1,459	160.39	$234,009.01	0	4
2024-06-24	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	2,789	159.80	$445,682.20	0	4
2024-06-18	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	2,627	154.94	$407,027.38	0	4
2024-06-18	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	841	153.75	$129,303.75	0	4
2024-06-17	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	1,281	159.28	$204,037.68	0	4
2024-06-17	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	439	159.21	$69,893.19	0	4
2024-06-17	Wang, Julia Aijun	Officer	Chief Financial Officer	Direct	Sale	916	158.89	$145,543.24	0	4
2024-04-11	Oyler, John	Director,Officer	Chief Executive Officer	Indirect	Sale	12,084	146.88	$1,774,897.92	0	4
2024-03-13	Oyler, John	Director,Officer	Chief Executive Officer	Direct	Sale	12,332	179.92	$2,218,773.44	0	4
2024-02-29	Wang, Julia Aijun	Officer	Chief Financial Officer	Direct	Sale	397	167.08	$66,330.76	0	4
2023-11-14	Baker, Brothers Life Scie…	Director,TenPercentOwner	-	Indirect	Sale	1,100,000	180.50	$198,550,000.00	877,603	4
2023-07-31	Lee, Chan Henry	Officer	SVP, General Counsel	Direct	Sale	791	216.26	$171,061.66	0	4
2023-07-03	Wang, Julia Aijun	Officer	Chief Financial Officer	Direct	Sale	472	179.55	$84,747.60	0	4
2023-06-26	Wu, Xiaobin	Officer	President, COO & GM China	Direct	Sale	1,495	182.37	$272,643.15	0	4
2023-06-26	Wang, Lai	Officer	Global Head of R&D	Direct	Sale	1,108	182.53	$202,243.24	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

30.70%

Inst. Shares: 34,066,399

Shares Outstanding: 110,957,836

2025-12-31

29.60%

Inst. Shares: 32,283,487

Shares Outstanding: 109,061,825

2025-09-30

27.97%

Inst. Shares: 30,830,839

Shares Outstanding: 110,215,515

2025-06-30

30.65%

Inst. Shares: 33,202,396

Shares Outstanding: 108,320,520

2025-03-31

33.51%

Inst. Shares: 35,831,702

Shares Outstanding: 106,927,151

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	34,066,399	110,957,836	30.70%
2025-12-31	32,283,487	109,061,825	29.60%
2025-09-30	30,830,839	110,215,515	27.97%
2025-06-30	33,202,396	108,320,520	30.65%
2025-03-31	35,831,702	106,927,151	33.51%
2024-12-31	40,494,047	105,288,215	38.46%
2024-09-30	43,331,039	105,903,990	40.92%
2024-06-30	44,146,820	104,698,659	42.17%
2024-03-31	43,807,990	104,272,894	42.01%
2023-12-31	42,176,978	104,387,273	40.40%
2023-09-30	44,210,637	104,670,483	42.24%
2023-06-30	43,952,002	104,632,644	42.01%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

BeOne Medicines Ltd. (ONC) — SEC Financial Statements & Analysis

BeOne Medicines Ltd. (ONC) is a pharmaceutical preparations company. BeOne Medicines Ltd. trades on Nasdaq, OTC as: ONC, BEIGF. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BeOne Medicines Ltd. reported a 34.35% year-over-year revenue growth, a Gross Profit Margin of 88.89% (TTM), a Debt-to-Equity ratio of 0.77x, a Price-to-Sales (P/S) ratio of 5.19x (TTM), a Price-to-Book (P/B) ratio of 6.15x (TTM), at a market cap of $31.80B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 34.35%
Gross Profit Margin TTM: 88.89%
Debt To Equity: 0.77x
P/S TTM: 5.19x
P/B TTM: 6.15x
Market Cap: $31.80B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BeOne Medicines Ltd. in?

BeOne Medicines Ltd. (ONC) operates in the Pharmaceutical Preparations industry.

What is ONC's market cap?

BeOne Medicines Ltd. (ONC) has a market capitalization of $31.80B as of 2026-06-30.

What is ONC's P/E ratio?

BeOne Medicines Ltd. (ONC)'s trailing twelve month P/E ratio is 48.49x as of 2026-06-30.

What exchange does ONC trade on?

BeOne Medicines Ltd. (ONC) trades on the Nasdaq, OTC.